NO20071312L - Bindinger som er monovalente for CD40L binding og framgangsmate for bruk - Google Patents

Bindinger som er monovalente for CD40L binding og framgangsmate for bruk

Info

Publication number
NO20071312L
NO20071312L NO20071312A NO20071312A NO20071312L NO 20071312 L NO20071312 L NO 20071312L NO 20071312 A NO20071312 A NO 20071312A NO 20071312 A NO20071312 A NO 20071312A NO 20071312 L NO20071312 L NO 20071312L
Authority
NO
Norway
Prior art keywords
cd40l
antibody polypeptide
monovalent
activity
methods
Prior art date
Application number
NO20071312A
Other languages
English (en)
Norwegian (no)
Inventor
Steven Grant
Haiqun Liu
Kevin Moulder
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36074265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071312(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20071312L publication Critical patent/NO20071312L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20071312A 2004-09-17 2007-03-12 Bindinger som er monovalente for CD40L binding og framgangsmate for bruk NO20071312L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61081904P 2004-09-17 2004-09-17
US11/102,512 US7563443B2 (en) 2004-09-17 2005-04-08 Monovalent anti-CD40L antibody polypeptides and compositions thereof
PCT/GB2005/003562 WO2006030220A1 (en) 2004-09-17 2005-09-16 Compositions monovalent for cd40l binding and methods of use

Publications (1)

Publication Number Publication Date
NO20071312L true NO20071312L (no) 2007-06-08

Family

ID=36074265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071312A NO20071312L (no) 2004-09-17 2007-03-12 Bindinger som er monovalente for CD40L binding og framgangsmate for bruk

Country Status (16)

Country Link
US (5) US7563443B2 (ja)
EP (2) EP2371862A3 (ja)
JP (1) JP5808880B2 (ja)
KR (2) KR20130039341A (ja)
AU (1) AU2005283932B8 (ja)
BR (1) BRPI0515404A (ja)
CA (1) CA2581017C (ja)
ES (1) ES2442455T3 (ja)
GE (1) GEP20125471B (ja)
HK (1) HK1101182A1 (ja)
IL (1) IL181724A (ja)
MX (1) MX2007003187A (ja)
NO (1) NO20071312L (ja)
NZ (1) NZ553847A (ja)
RU (1) RU2364420C2 (ja)
WO (1) WO2006030220A1 (ja)

Families Citing this family (371)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
PT1639011E (pt) * 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518761A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2006224438A1 (en) * 2005-03-18 2006-09-21 Antonio Cassone Antibodies against Candida antigens
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006108035A1 (en) 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
KR20080049113A (ko) * 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CN101479375B (zh) * 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
CN101563363B (zh) 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 用于治疗疾病的靶向补体因子h
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EA019636B1 (ru) 2007-03-22 2014-05-30 Байоджен Айдек Ма Инк. Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009004065A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CA2730316A1 (en) 2008-07-11 2010-01-14 Phylogica Limited Peptide inhibitors of cd40l signaling and uses therefor
JP2012507260A (ja) * 2008-07-18 2012-03-29 ドマンティス リミテッド Ｃｄ２８結合のための一価の組成物及び使用方法
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
CA2746395C (en) 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
AU2009333489A1 (en) * 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-TNF antibodies in patients with ankylosing spondylitis
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
RU2539798C2 (ru) 2009-04-10 2015-01-27 Аблинкс Нв Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
PL2896404T3 (pl) * 2009-06-04 2017-12-29 Novartis Ag Sposoby identyfikacji miejsc koniugacji IgG
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
SG177601A1 (en) * 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
EA026097B1 (ru) * 2009-07-29 2017-03-31 Глаксо Груп Лимитед Однодоменные антитела против рецептора tgf-бета ii типа
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx Nv Formulações estáveis de polipéptidos e seus usos
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
HUE040306T2 (hu) 2009-09-24 2019-03-28 Ucb Biopharma Sprl Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént
AU2010314931A1 (en) 2009-11-05 2012-06-21 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
WO2011095545A1 (en) 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2533761B1 (en) 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
KR101853405B1 (ko) * 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
WO2012056000A1 (en) 2010-10-29 2012-05-03 Ablynx Nv Method for the production of immunoglobulin single variable domains
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
JP2014501515A (ja) * 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
MX354243B (es) 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
HUE035674T2 (en) 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strains expressing recombinant DSBC
WO2013014208A2 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
BR112014009069A2 (pt) * 2011-10-13 2020-10-27 Bristol-Myers Squibb Company polipeptídeos de anticorpo que antagonizam cd40l
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
EP2791168A1 (en) 2011-11-23 2014-10-22 Amgen Inc. Methods of treatment using an antibody against interferon gamma
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
WO2013169338A1 (en) * 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
EP2875046B1 (en) 2012-07-19 2020-02-26 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
WO2014062535A1 (en) * 2012-10-15 2014-04-24 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US11059910B2 (en) * 2012-12-03 2021-07-13 Novimmune Sa Anti-CD47 antibodies and methods of use thereof
WO2014177595A1 (en) 2013-04-29 2014-11-06 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG11201702688UA (en) 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
HUE044199T2 (hu) 2014-10-10 2019-10-28 Ablynx Nv Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
US10858666B2 (en) 2014-11-05 2020-12-08 Biotalys Transgenic plants expressing a variable domain of a heavy chain antibody (VHH) that binds to a sphingolipid of a fungus
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3253791A1 (en) 2015-02-03 2017-12-13 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-rho gtpase conformational single domain antibodies and uses thereof
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
SI3294319T1 (sl) 2015-05-13 2024-09-30 Ablynx Nv Polipeptidi, ki rekrutirajo celice T na osnovi reaktivnosti CD3
PL3294768T3 (pl) 2015-05-13 2020-03-31 Ablynx N.V. Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta
WO2017024146A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US20170059561A1 (en) * 2015-08-28 2017-03-02 The Florida International University Board Of Trustees Thermally Stable Electrochemical Sensor With Long Shelf-Life
US11078251B2 (en) 2015-09-18 2021-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
US10947598B2 (en) 2015-09-29 2021-03-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining the metabolic status of lymphomas
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
US10556953B2 (en) 2015-10-12 2020-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
EP3374389A1 (en) 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
MA43302A (fr) 2015-11-27 2021-03-17 Ablynx Nv Polypeptides inhibant le ligand cd40l
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
ES2837155T3 (es) 2016-01-04 2021-06-29 Inst Nat Sante Rech Med Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
EP3407912B1 (en) 2016-01-28 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
EP3439659A1 (en) 2016-04-06 2019-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
US20190125826A1 (en) 2016-04-22 2019-05-02 Inserm (Institut National De La Santé Et De La Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
CN109310788A (zh) 2016-05-03 2019-02-05 法国国家健康和医学研究院 Cd31shed作为分子靶标用于炎症成像
US11376269B2 (en) 2016-05-06 2022-07-05 Inserm Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
US20190292259A1 (en) 2016-05-24 2019-09-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2017202890A1 (en) 2016-05-27 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating myeloma
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
AU2017324983A1 (en) * 2016-09-07 2019-04-18 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
WO2018046610A1 (en) 2016-09-08 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018087391A1 (en) 2016-11-14 2018-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018091621A1 (en) 2016-11-17 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for increasing endogenous protein level
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
WO2018134389A1 (en) 2017-01-23 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating infections
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3589725A1 (en) 2017-02-28 2020-01-08 Vib Vzw Means and methods for oral protein delivery
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
US20210186982A1 (en) 2017-03-24 2021-06-24 Universite Nice Sophia Antipolis Methods and compositions for treating melanoma
WO2018178030A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178029A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
JP7278960B2 (ja) 2017-03-28 2023-05-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新規タウ種
WO2018178237A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of mitochondrial genetic diseases
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
JP2020521745A (ja) * 2017-05-24 2020-07-27 エイエルエス・セラピー・デベロップメント・インスティテュートＡＬＳ Ｔｈｅｒａｐｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｉｎｓｔｉｔｕｔｅ 治療用抗ｃｄ４０リガンド抗体
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
CN110997716B (zh) 2017-06-02 2024-03-15 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
CN110997717A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 结合adamts5、mmp13和聚蛋白聚糖的多肽
EP3635398B1 (en) 2017-06-08 2024-07-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Chimeric receptor for use in whole-cell sensors for detecting analytes of interest
WO2018224615A1 (en) 2017-06-08 2018-12-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating hyperpigmentation disorders
EP3641802A1 (en) 2017-06-22 2020-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
WO2019016310A1 (en) 2017-07-20 2019-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND COMPOSITIONS FOR TREATING CANCERS
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
WO2019043026A1 (en) 2017-08-30 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
EP3457139A1 (en) 2017-09-19 2019-03-20 Promise Advanced Proteomics Antibody-like peptides for quantifying therapeutic antibodies
AU2018335828A1 (en) * 2017-09-19 2020-03-05 Mab Discovery Gmbh Agonistic CD40 antibodies
EP3684471A1 (en) 2017-09-20 2020-07-29 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for modulating autophagy
EP3704160A1 (en) 2017-10-31 2020-09-09 VIB vzw Novel antigen-binding chimeric proteins and methods and uses thereof
EP3710486A1 (en) 2017-11-15 2020-09-23 Novo Nordisk A/S Factor x binders enhancing fx activation
WO2019101995A1 (en) 2017-11-27 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for cardiac regeneration
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019145413A1 (en) 2018-01-25 2019-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
BR112020015991A2 (pt) 2018-02-06 2020-12-15 Ablynx N.V. Métodos de tratamento de episódio inicial de ttp com domínios variáveis únicos de imunoglobulina
US20210061917A1 (en) 2018-02-16 2021-03-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and compositions for treating vitiligo
CA3092421A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
CN116942851A (zh) 2018-03-23 2023-10-27 布鲁塞尔自由大学 Wnt信号传递激动剂分子
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
JP7444858B2 (ja) 2018-09-05 2024-03-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 喘息及びアレルギー性疾患を処置するための方法及び組成物
EP3849545A1 (en) 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis
US20220048995A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
US20220023265A1 (en) 2018-09-17 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US20220033486A1 (en) 2018-09-25 2022-02-03 Inserm (Institut National De La Santè Et De La Recherch Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
JP2022512626A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
JP2022512648A (ja) 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
WO2020079162A1 (en) 2018-10-18 2020-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inducing full ablation of hematopoiesis
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020120644A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
US20220073626A1 (en) 2019-01-03 2022-03-10 Institut National De La Santé Et De La Recheche Médicale (Inserm) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
EP3935391B1 (en) 2019-03-05 2024-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for renal cell carcinoma
EP4378485A3 (en) 2019-03-08 2024-08-28 LinXis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2020201442A1 (en) 2019-04-03 2020-10-08 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US20220259295A1 (en) 2019-06-20 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method useful in tolerance induction therapy and kits therefore
US20220275105A1 (en) 2019-08-02 2022-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021078359A1 (en) 2019-10-21 2021-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of cubilin for the treatment of chronic kidney diseases
WO2021094308A1 (en) 2019-11-12 2021-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New serological marker for the latent form of toxoplasmosis
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2023514957A (ja) 2020-02-28 2023-04-12 オレガ・バイオテック Ｃｔｌａ４阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
BR112022019728A2 (pt) 2020-03-31 2022-11-22 Biotalys NV Polipeptídeos antifúngicos
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
EP4144758A4 (en) 2020-04-22 2024-05-15 Mabwell (Shanghai) Bioscience Co., Ltd. SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
CN115551553A (zh) 2020-05-12 2022-12-30 Inserm(法国国家健康医学研究院) 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
CA3182339A1 (en) 2020-05-20 2021-11-25 Institut Curie Synthetic single domain library
CN115968377A (zh) 2020-05-20 2023-04-14 居里研究所 单域抗体及其在癌症治疗中的用途
JP2023527578A (ja) 2020-06-05 2023-06-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 眼疾患を処置するための方法及び医薬組成物
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
TW202214844A (zh) 2020-06-17 2022-04-16 美商健生生物科技公司 用於製造多能幹細胞之材料及方法
AU2021299932A1 (en) 2020-06-29 2023-02-02 Assistance Publique-Hôpitaux De Paris (Aphp) Anti-protein S single-domain antibodies and polypeptides comprising thereof
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
US20240325562A1 (en) 2020-09-16 2024-10-03 Linxis B.V. Internalizing binding molecules
EP4216943A1 (en) 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022096547A1 (en) 2020-11-05 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
US20230416830A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
MX2023006604A (es) 2020-12-04 2023-06-19 Tidal Therapeutics Inc Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
TW202222840A (zh) 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
KR20230147616A (ko) 2021-01-11 2023-10-23 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용
CN116568811A (zh) 2021-01-13 2023-08-08 上海华奥泰生物药业股份有限公司 结合cd73的蛋白及其应用
US20240317890A1 (en) 2021-01-14 2024-09-26 Institut Curie Her2 single domain antibodies variants and cars thereof
CN116963773A (zh) 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
CN116917321A (zh) 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1的单域抗体及其用途
EP4296284A1 (en) 2021-02-19 2023-12-27 SHAPERON Inc. Bispecific single domain antibody to pd-l1 and cd47 and use thereof
IL305301A (en) 2021-02-19 2023-10-01 Us Health Single domain antibodies neutralizing SARS CoV-2
CN116964095A (zh) 2021-02-19 2023-10-27 沙裴隆有限公司 针对cd47的单域抗体及其用途
US20240165094A1 (en) 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
WO2022199527A1 (zh) 2021-03-22 2022-09-29 星济生物(苏州)有限公司 靶向肺炎链球菌溶血素的抗原结合蛋白及其用途
JP2024512567A (ja) 2021-03-23 2024-03-19 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Ｔ細胞リンパ腫の診断および治療方法
US20240182562A1 (en) 2021-04-02 2024-06-06 Oricell Therapeutics Co., Ltd Cldn18.2 antigen-binding protein and use thereof
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
WO2022223488A1 (en) 2021-04-19 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
IL309559A (en) 2021-07-09 2024-02-01 Luxembourg Inst Of Health Lih Dimeric protein complexes and their uses
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
US20240279336A1 (en) 2021-07-30 2024-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric proteins and methods of immunotherapy
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
CN116178561A (zh) 2021-11-26 2023-05-30 杭州尚健生物技术有限公司 包含SIRPα突变体的融合蛋白
EP4448095A1 (en) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4209508A1 (en) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanobodies for the deneddylating enzyme nedp1
WO2023144235A1 (en) 2022-01-27 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4231017A1 (en) 2022-02-17 2023-08-23 Promise Proteomics Detection and quantification of anti-drug antibodies and anti-self antibodies
TW202400242A (zh) 2022-03-14 2024-01-01 大陸商上海華奧泰生物藥業股份有限公司 抗體藥物偶聯物及其應用
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023237661A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4299124A1 (en) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2 nanobodies for use as biomolecule transporter
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024013234A1 (en) 2022-07-13 2024-01-18 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis, prognosis, stratification and treating of myocarditis
WO2024018003A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024038112A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
WO2024126685A1 (en) 2022-12-15 2024-06-20 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024145551A1 (en) 2022-12-29 2024-07-04 Biotalys NV Agrochemical compositions
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024165823A2 (fr) 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
WO2024175760A1 (en) 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
WO2024200846A1 (en) 2023-03-30 2024-10-03 272BIO Limited Gnrh-binding polypeptides and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE307996B (ja) 1965-11-30 1969-01-27 Asea Ab
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
JP3102439B2 (ja) 1991-09-03 2000-10-23 カーツクロウ リミテッド 車両進行制止装置
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1994004678A1 (en) * 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
CN1137726C (zh) 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ATE188487T1 (de) * 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6346274B1 (en) 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
GB2302024B (en) 1995-06-09 1998-10-07 Malix Polymer Engineering Limi Obstetric vacuum extractor
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
EA004401B1 (ru) * 1996-07-08 2004-04-29 Дзе Трастиз Оф Колумбия Юниверсити Ин Дзе Сити Оф Нью Йорк Терапевтическое применение т-вам(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры
AU8800598A (en) 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
JP2002507967A (ja) 1997-06-20 2002-03-12 パンゲネチックス・ベー・ファウ 疾病治療のための抗ｃｄ４０ｌイムノトキシン
WO1999000143A1 (en) 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
EP1071400B1 (en) 1998-04-20 2004-11-03 Genzyme Corporation Drug delivery of proteins from polymeric blends
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2003502024A (ja) 1999-05-14 2003-01-21 メディカル リサーチ カウンシル タンパク質骨格および単量体ポリペプチドを多量体化するためのその使用
FI991456A (fi) 1999-06-24 2000-12-25 Nokia Networks Oy EMI-tiivistys
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1299542A2 (en) 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
EP1320590A2 (en) 2000-07-13 2003-06-25 Millennium Pharmaceuticals, Inc. 47885, a novel human ubiquitin-activating enzyme and uses therefor
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
JP5133494B2 (ja) * 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
WO2003031611A2 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof

Also Published As

Publication number Publication date
JP2008513425A (ja) 2008-05-01
US7563443B2 (en) 2009-07-21
MX2007003187A (es) 2008-01-16
RU2007114266A (ru) 2008-10-27
US20090297524A1 (en) 2009-12-03
RU2364420C2 (ru) 2009-08-20
US20100092483A1 (en) 2010-04-15
EP2371862A3 (en) 2012-10-24
EP1797126A1 (en) 2007-06-20
IL181724A0 (en) 2007-07-04
IL181724A (en) 2012-08-30
KR20130039341A (ko) 2013-04-19
CA2581017A1 (en) 2006-03-23
WO2006030220A9 (en) 2006-10-19
AU2005283932A1 (en) 2006-03-23
KR101360140B1 (ko) 2014-02-20
AU2005283932B8 (en) 2012-01-19
AU2005283932B2 (en) 2012-01-12
BRPI0515404A (pt) 2007-11-27
HK1101182A1 (en) 2007-10-12
WO2006030220A1 (en) 2006-03-23
GEP20125471B (en) 2012-04-25
JP5808880B2 (ja) 2015-11-10
EP1797126B1 (en) 2013-10-23
ES2442455T3 (es) 2014-02-11
US20100092482A1 (en) 2010-04-15
NZ553847A (en) 2010-01-29
US7927596B2 (en) 2011-04-19
US7829096B2 (en) 2010-11-09
KR20070057953A (ko) 2007-06-07
US20110172400A1 (en) 2011-07-14
US20060062784A1 (en) 2006-03-23
US8524236B2 (en) 2013-09-03
EP2371862A2 (en) 2011-10-05
CA2581017C (en) 2016-10-11

Similar Documents

Publication Publication Date Title
NO20071312L (no) Bindinger som er monovalente for CD40L binding og framgangsmate for bruk
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
NO20070189L (no) Immunoglobuliner
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
NO20082767L (no) Kimaere og humaniserte anti-humane IL-13 antistoffer
WO2004004633A3 (en) Use of tnfalpha antibodies and another drug
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
HRP20060033B1 (hr) Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute
RU2008119689A (ru) Человеческие антитела к il-13 и их терапевтическое применение
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
NO20071788L (no) Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav.
ME00226B (me) Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
WO2022040603A3 (en) Single-domain antibodies that bind sars-cov-2
WO2010007376A3 (en) Compositions monovalent for cd28 binding and methods of use
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2008083169A3 (en) Compositions and methods for the treatment of immunologic disorders
NO20081453L (no) Sammensetninger og fremgangsmater for diagnostisering og behandling av inflammasjon
JP2012523221A5 (ja)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application